Latest Oncology News

Page 2 of 27
Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.
Ada Torres
Ada Torres
4 June 2026
Chimeric Therapeutics reports encouraging Phase 1/2 data for its CHM CDH17 CAR-T therapy in advanced gastrointestinal cancers, with 82% of evaluable patients achieving stable disease and durable responses lasting over a year.
Ada Torres
Ada Torres
1 June 2026
Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.
Ada Torres
Ada Torres
29 May 2026
Racura Oncology has locked in an underwriting agreement covering nearly 1.84 million expiring options, ensuring up to $2.3 million in fresh capital to back its cancer drug development programs.
Ada Torres
Ada Torres
28 May 2026
Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.
Ada Torres
Ada Torres
28 May 2026
Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.
Ada Torres
Ada Torres
28 May 2026
Noxopharm has unveiled new data showing its Sofra technology dramatically boosts TLR8 activation, a key immune pathway, potentially reshaping cancer immunotherapy.
Ada Torres
Ada Torres
26 May 2026
AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.
Ada Torres
Ada Torres
25 May 2026
TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.
Ada Torres
Ada Torres
22 May 2026
Imugene Limited’s allogeneic CAR T therapy, azer-cel, delivered an 81% overall response rate in a Phase 1b trial cohort of CAR T-naïve patients with various CD19 B-cell malignancies, with updated data due at ASCO 2026.
Ada Torres
Ada Torres
22 May 2026
IMEXHS Limited exceeded FY25 revenue and EBITDA guidance, driven by strategic contract wins and AI-powered workflow automation. The company projects stronger software growth and sustained profitability in FY26.
Ada Torres
Ada Torres
20 May 2026
OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.
Ada Torres
Ada Torres
20 May 2026